Our Take
ResMap is a validated screening framework and dataset, not a drug candidate—it accelerates the hunt for persister therapies but does not itself reach the clinic.
Why it matters
Cancer relapse driven by persister cells has frustrated oncology for over a decade with no approved therapies. A standardized, reproducible screening platform shifts this from speculation to systematic target validation.
Do this week
Oncology teams: audit your current persister combination strategies against the nine validated targets ResMap identified, then prioritize which ones fit your patient population and resistance profiles.
UCSF built and deployed a robotic screening platform
Researchers at the University of California, San Francisco developed ResMap, an automated high-throughput system designed to identify and test drugs against therapy-resistant persister cells. The platform combines robotic liquid handling, acoustic drug deposition, microscopic imaging, and machine learning-based data normalization to screen thousands of miniature tumors in parallel.
The team screened 94 candidate drugs flagged by prior research against persister cells derived from four lung cancer models: two EGFR-mutant lines treated with osimertinib, and two KRAS G12C lines treated with sotorasib. Each model was tested under both normal and hypoxic oxygen conditions. Results appear in Science Advances under the title "ResMap: A community resource for systematic mapping of therapy-persistent residual cancer cell dependencies across contexts" (Xiaoxiao Sun, first author).
Of the 94 drugs tested, 12 initially showed conserved anti-persister activity across genotypes and oxygen environments. Follow-up validation confirmed nine targets with reproducible persister-specific activity relative to general cytotoxicity. The platform is now being released as a community resource with both the experimental framework and quantitative dataset available to other researchers.
Persister cells are rare (as few as one in a thousand tumor cells), genetically identical to the primary tumor, and exhibit survival traits that may fade once isolated in culture. The robotic automation was necessary to run 10,000 week-long experiments that would otherwise require manual labor and introduce unacceptable batch variability.
A decade of persister research had no unified testing framework
Cancer cell persistence was first described in 2010. Since then, studies have linked persister survival to different biological processes and generated an expanding list of candidate therapeutic targets. However, the field lacked a standardized experimental framework to compare vulnerabilities across tumor types and treatment conditions. No persister-directed therapy has reached clinical approval.
ResMap changes this by establishing reproducible evidence that persister cells may share common vulnerabilities despite emerging under different treatment regimens. The validated nine targets suggest that "targeting individual, well-chosen survival pathways may be sufficient to meaningfully reduce residual disease burden," according to the paper.
The shared dependencies across genotypes and oxygen conditions indicate potential rules governing persister biology, rather than each tumor behaving as a special case. This opens a path toward rational combination strategies: pairing standard oncogene-directed therapy with validated persister-directed drugs before relapse occurs.
Open-source dataset enables validation and combination design
ResMap is explicitly positioned as a community resource for coordinated validation efforts, not a proprietary screening service. Other laboratories can now benchmark their own candidates against the nine validated targets, reproduce results across new cancer models, and test combination approaches using the standardized workflow.
The UCSF team plans to expand the platform to additional tumor types and treatment conditions, broadening the generalizability of the findings. For oncology teams and biotech companies designing persister-directed therapies, the dataset provides both a benchmark for target selection and a framework for pre-clinical validation before moving to clinical trial design.